Bilypsa Tablet

Bilypsa Tablet, containing Saroglitazar 4 mg, is used mainly for:

• Diabetic dyslipidemia (abnormal cholesterol and triglyceride levels in type 2 diabetes)

• Hypertriglyceridemia

• Non-alcoholic fatty liver disease (NAFLD)

• Noncirrhotic non-alcoholic steatohepatitis (NASH).
  

  Bilypsa Tablet – Uses

  Bilypsa Tablet contains Saroglitazar 4 mg, a novel dual PPAR α/γ agonist developed by Zydus Cadila. It is primarily prescribed for the management of lipid and glucose metabolism disorders, especially in individuals with type 2 diabetes and liver-related complications.

  1. Diabetic Dyslipidemia

  Helps control abnormal cholesterol and triglyceride levels in patients with type 2 diabetes, particularly when standard statin therapy is insufficient.

  2. Hypertriglyceridemia

  Lowers elevated triglyceride levels, thereby reducing the risk of cardiovascular complications and other metabolic issues.

  3. Non-Alcoholic Fatty Liver Disease (NAFLD)

  Improves liver health by reducing fat accumulation and normalizing liver enzyme levels in patients with fatty liver unrelated to alcohol consumption.

  4. Noncirrhotic Non-Alcoholic Steatohepatitis (NASH)

  Alleviates liver inflammation and cellular damage in non-cirrhotic patients, helping to prevent disease progression.
  
  Disclaimer : 

  • Med E Hub is committed to delivering reliable, expert-reviewed information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment.

  ·         Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

  ·         Our goal is to complement, not replace, the essential doctor-patient relationship.